Clinician's Roundtable

Host: Raj Chovatiya, MD, PhD Guest: Jason E. Hawkes, MD, MS, FAAD Roflumilast and tapinarof are two of the new topical nonsteroidal therapies for plaque psoriasis that have several advantages over the traditional topical steroids. Learn more about how emerging topical nonsteroidals could impact your patients with plaque psoriasis with Dr. Raj Chovatiya and Dr. Jason Hawkes, a medical dermatologist in the Greater Sacramento area who also sits on the National Psoriasis Foundation Medical Board and Scientific Advisory Committee.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Dylan Baker, MD Georgia has the highest rate of new HIV diagnoses out of any state in the country, and so it’s imperative that we make this medication more accessible now in order to save future generations from living with HIV. To dive further into the benefits and challenges of this program, Dr. Mary Katherine Cheeley is joined by Dr. Dylan Baker, Assistant Professor of Medicine at Emory University and the Associate Medical Director of the Grady PrEP Clinic.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sorana Segal-Maurer, MD Research has shown that those living with HIV are more likely to be malnourished and experience nutrient deficiencies that play an essential role in their immunity. In the early days of HIV, a typical recommendation was to increase a patient’s calorie count. To discuss how the focus on nutrition has changed now that this patient population is living much longer, Dr. Charles Turck is joined by Dr. Sorana Segal-Maurer, Director of Infectious Diseases at New York-Presbyterian Queens and Professor of Clinical Medicine at Weill Cornell Medicine in New York City.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sorana Segal-Maurer, MD For most patients living with HIV, antiretroviral therapy is extremely effective. However, HIV mutates with frequency, allowing it to become resistant to antiviral medication. To discuss how we can effectively treat these patients, Dr. Charles Turck is joined by Dr. Sorana Segal-Maurer, Director of Infectious Diseases at New York-Presbyterian Queens and Professor of Clinical Medicine at Weill Cornell Medicine in New York City.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Sarah Bauerle Bass, PhD, MPH, FSBM Although the rate of new HIV diagnoses in the United States is steadily declining, people in prisons are still disproportionately living with the virus, which is why researchers at Temple University are now developing an app aimed at improving HIV prevention and substance use treatment access for incarcerated women in Philadelphia. To learn more about this research, Dr. Mary Katherine Cheeley is joined by Dr. Sarah Bauerle Bass, Associate Professor of Social and Behavioral Sciences and the Director of Risk Communication Laboratory at Temple University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kamel Khalili, PhD Scientists at Temple University’s Lewis Katz School of Medicine have identified a novel gene-editing strategy aimed at eliminating HIV-1 infection with no adverse effects on cell mortality. Find out how this recent discovery could get us one step closer to a cure for HIV with Dr. Charles Turck and Dr. Kamel Khalili, the Laura H. Carnell Professor in the Department of Neuroscience and Chair of the Department of Microbiology, Immunology & Inflammation.

Host: Michael Greenberg, MD Guest: William E. Hauter, MD Illinois lawmakers are taking steps to end intrusive mental health questionnaires for physician licensures. To learn more about Illinois House Bill 3109 and how you can get involved, join Dr. Michael Greenberg as he sits down with Dr. Bill Hauter, Illinois State Representative and Anesthesiologist.

Host: Mario R. Nacinovich, Jr., MSc Guest: Sally L. Baxter, MD, MSc The All of Us Research Program discovered associations between socioeconomic factors and visit adherence among patients with glaucoma. Can clinicians use this data to improve visit adherence? Mario Nacinovich joins Dr. Sally Baxter, an Assistant Professor of Ophthalmology and Biomedical Informatics at the University of California-San Diego, to take a look at this data.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Carl P. Walther, MD The alternative complement pathway and the lectin pathway are the two pathways that are important in IgA nephropathy (IgAN). So how does the dysregulation of these two pathways impact disease progression, and how might this knowledge help us optimize our approach to treating patients with IgAN? Joining Dr. Charles Turck to answer those and other key questions is nephrology specialist Dr. Carl Walther.

Host: Frank Cortazar, MD There are several challenges associated with the management of glomerular diseases like IgA nephropathy and C3 glomerulopathy. But in order to overcome those challenges, we must first have a firm understanding of them. That’s why Dr. Frank Cortazar from the New York Nephrology Vasculitis and Glomerular Center is here to break down those common challenges so we can work to better manage IgA nephropathy and C3 glomerulopathy.